The current study comprehensively included three types of biologics for the first time, i.e., TNF-α inhibitors, IL-17 inhibitors, and JAK inhibitors, involving 9 drugs (adalimumab, etanercept, golimumab, infliximab, secukinumab, bimekizumab, ixekizumab, tofacitinib, and upadacitinib) to analyze the impact of these drugs on the risk of new and recurrent uveitis in AS patients. The gene discussed is IL17A; the disease is uveitis.